Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

USP Draft Medicare Formulary Sets 146 Drug Categories And Classes

Executive Summary

U.S. Pharmacopeia's draft model for Medicare prescription drug formularies establishes 146 unique therapeutic categories and pharmacologic classes, falling in between the numbers of drug groups sought by drug manufacturers and PBMs
Advertisement

Related Content

USP “Key Drug Types” Could Serve As CMS Standard For Medicare Rx Plans
USP Final Formulary Guide Adds PPI Class, But Has Few Other Changes
Medicare Formulary Guide Looks Beyond USP For Principles On Rx Classes
PBMs’ Medicare Formulary Lobbying Takes On New Dimensions
Dual-Eligible Switch Poses New Barriers To Drug Access – Consultant
Medicare Formularies Should Ensure Off-Label Rx Coverage – Neurologist
Rx Discounts Do Not Require Restrictive Formularies, PhRMA Tells USP
CMS Considering Obesity Drug Coverage Under Medicare Rx Benefit
COX-2s, Statins Have No Class In USP Medicare Draft Formulary
Formulary Balancing Act: Medicare Rules Weigh Access Versus Cost Control

Topics

Advertisement
UsernamePublicRestriction

Register

PS044557

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel